Skip to main content
. 2018 Sep 12;92(19):e01087-18. doi: 10.1128/JVI.01087-18

FIG 2.

FIG 2

The effect of ITPA siRNA transfection and ribavirin treatment on HCV replication (A and B) and efficiency of ITPA siRNA transfection (C and D). (A) HCV RNA expression in HCV-infected Huh7.5 cells transfected with ITPA siRNA or a negative-control siRNA and ribavirin treatment as determined by real-time PCR and normalized to RPL4 expression. (B) HCV core antigen production in the supernatant of HCV-infected ITPA siRNA- or negative-control siRNA-transfected and ribavirin-treated Huh7.5 cells. (C) Efficiency of ITPA siRNA transfection on ITPA RNA expression in Huh7.5 cells transfected with ITPA siRNA or negative-control siRNA as determined by real-time PCR and normalized to RPL4 expression. (D) ITPA protein expression in Huh7.5 cells transfected with ITPA siRNA or negative-control siRNA and normalized to beta-actin protein levels as determined by immunoblotting. (E) Toxicity of ribavirin and siRNA treatment was determined by a proliferation assay of Huh7.5 cells treated with ribavirin and ITPA siRNA or a negative-control siRNA. Statistical significance was determined by a t test on logarithmic values (**, P < 0.01; ***, P < 0.001).